Denali Therapeutics (BSP:D2NL34) Total Liabilities: R$1,653.94 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:D2NL34 Denali Therapeutics Inc BSP:D2NL34
6 GF Score
Price R$27.06
! 6 Warning Signs
View Full Analysis

What is Denali Therapeutics Total Liabilities?

Denali Therapeutics BSP:D2NL34 6 Total Liabilities is R$1,653.94 Mil as of Jun. 2026. GuruFocus rates BSP:D2NL34 with a GF Score™ of 6/100. The stock has 6 warning signs investors should review.

Denali Therapeutics's Total Liabilities for the quarter that ended in Jun. 2026 was R$1,653.94 Mil.

Denali Therapeutics's quarterly Total Liabilities increased from Dec. 2025 (R$715.20 Mil) to Mar. 2026 (R$1,777.67 Mil) but then declined from Mar. 2026 (R$1,777.67 Mil) to Jun. 2026 (R$1,653.94 Mil).

Denali Therapeutics's annual Total Liabilities increased from Dec. 2023 (R$602.49 Mil) to Dec. 2024 (R$881.57 Mil) but then declined from Dec. 2024 (R$881.57 Mil) to Dec. 2025 (R$715.20 Mil).

Denali Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Denali Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Denali Therapeutics Total Liabilities Chart

Denali Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,498.74 2,191.59 602.49 881.57 715.20

Denali Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 771.91 694.10 715.20 1,777.67 1,653.94
BSP:D2NL34
6GF Score
Denali Therapeutics Inc BSP:D2NL34
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Denali Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Denali Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=536.574+(148.45+30.18
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=715.20

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=6245.98-5530.776
=715.20

Denali Therapeutics's Total Liabilities for the quarter that ended in Jun. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=461.594+(112.863+28.076
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+1051.409+0+0)
=1,653.94

Total Liabilities=Total Assets (Q: Jun. 2026 )-Total Equity (Q: Jun. 2026 )
=5933.477-4279.536
=1,653.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of R$1,653.94 Mil mean?
Denali Therapeutics (BSP:D2NL34) has a Total Liabilities of R$1,653.94 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Denali Therapeutics and its competitors.
Is Denali Therapeutics' Total Liabilities too high?
Denali Therapeutics' current Total Liabilities is R$1,653.94 Mil. Overall, Denali Therapeutics has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Denali Therapeutics' Total Liabilities compare to RCUS and ALMS?
Denali Therapeutics' Total Liabilities of R$1,653.94 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Denali Therapeutics and its competitors. Denali Therapeutics's current Total Liabilities is R$1,653.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Denali Therapeutics stock overvalued right now?
Denali Therapeutics (BSP:D2NL34) has a current Total Liabilities of R$1,653.94 Mil. The current Total Liabilities is R$1,653.94 Mil. Denali Therapeutics' overall GF Score™ is 6/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Denali Therapeutics (BSP:D2NL34), the current Total Liabilities is R$1,653.94 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Denali Therapeutics Business Description

Other Exchanges DNLI:USA4DN:Germany
Address 161 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
6GF Score

Get the complete analysis for BSP:D2NL34

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$27.06
Price